GlassScriptPhysician profile
Timothy Leichliter
NPI 1649568379
$99,265.25
in general payments reported to CMS, 2019-2025
19 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $2,437 · 2021: $7,320 · 2022: $11K · 2023: $16K · 2024: $31K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $20K · Food and Beverage: $3,348 · Travel and Lodging: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,174.48 |
| Consulting Fee | $20,000.00 |
| Food and Beverage | $3,348.08 |
| Travel and Lodging | $2,308.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $66,580.55 | 2020-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $29,135.38 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $1,500.00 | 2019 | |
| Mdd US Operations, LLC | $524.54 | 2019-2025 | Gocovri |
| Abbvie INC. | $474.13 | 2022-2025 | |
| Boston Scientific Corporation | $374.00 | 2019-2025 | General - Dbs |
| Lundbeck LLC | $148.00 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $139.33 | 2019-2024 | Rytary |
| Acadia Pharmaceuticals INC | $79.47 | 2024-2025 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $58.12 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $49.08 | 2024-2025 | Keveyis |
| Vertical Pharmaceuticals, LLC | $41.98 | 2019 | |
| Revance Therapeutics, INC. | $29.49 | 2024 | Daxxify |
| Merz North America, INC. | $29.07 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.92 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $22.42 | 2024 | Cholbam |
| Kyowa Kirin, INC. | $21.27 | 2024 | Nourianz |
| Medtronic USA, INC. | $16.57 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Leichliter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.